The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report
- 21 July 2020
- journal article
- research article
- Published by S. Karger AG in Nephron
- Vol. 144 (9), 459-462
- https://doi.org/10.1159/000509738
Abstract
The SARS-COV-2-19-associated respiratory involvement is caused by the massive release of inflammatory cytokines ultimately leading to interstitial pneumonia and acute respiratory distress syndrome (ARDS). In the absence of an effective antiviral treatment, a reasonable causal approach could be constituted by the neutralization of these substances. The authors describe the clinical course of a patient with SARS-COV-2-19 interstitial pneumonia treated with the combination of an anti-interleukin 6 (IL-6) agent (tocilizumab) and hemoadsorption (HA). This combination was used to abate the surge of inflammatory mediators leading to the lung damage. Blood levels of IL-6 and C-reactive protein (CRP) were measured before the initiation of the treatment and in the following 3 days. At the end of the treatment, the values of IL-6 and CRP decreased from 1,040 to 415 pg/mL and from 229 to 59 mg/L, respectively. The gas exchanges and the chest imaging rapidly improved, and the patient was extubated 10 days later. The combination of tocilizumab and HA could be valuable in the treatment of SARS-COV-2-19-associated pneumonia and ARDS that are caused by the release of inflammatory mediators.Keywords
This publication has 16 references indexed in Scilit:
- Discovering drugs to treat coronavirus disease 2019 (COVID-19)Drug Discoveries & Therapeutics, 2020
- Changes in Cytokines, Haemodynamics and Microcirculation in Patients with Sepsis/Septic Shock Undergoing Continuous Renal Replacement Therapy and Blood Purification with CytoSorbBlood Purification, 2020
- Multimodal Therapeutic Approach of Cytokine Release Syndrome Developing in a Child Given Chimeric Antigen Receptor-Modified T Cell InfusionCritical Care Explorations, 2020
- Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective studyCritical Care, 2019
- In vitro comparison of the adsorption of inflammatory mediators by blood purification devicesIntensive Care Medicine Experimental, 2018
- Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb® sorbent porous polymer beadsPLOS ONE, 2018
- Pretenders and Contenders: Inflammation, C‐Reactive Protein, and Interleukin‐6Journal of the American Heart Association, 2017
- Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsisBMC Medicine, 2017
- Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic SyndromeArthritis & Rheumatology, 2014
- Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infectionCritical Care, 2011